Levicept Taps F-star Veteran as CFO Amid LEVI-04 Development Push
Event summary
- Darlene Deptula-Hicks appointed CFO of Levicept, replacing Nicholas Stern.
- Deptula-Hicks previously led F-star Therapeutics' $85M follow-on offering and Nasdaq listing.
- Levicept's LEVI-04 completed Phase II trial with 500+ patients showing pain relief and potential disease modification.
- LEVI-04 targets osteoarthritis market estimated at over $10B.
The big picture
Levicept's appointment of Deptula-Hicks signals preparation for significant capital raises or strategic transactions as it advances LEVI-04, a potential first-in-class osteoarthritis treatment. The move comes amid growing competition in the chronic pain market and follows positive Phase II results positioning LEVI-04 as a novel non-opioid therapeutic option.
What we're watching
- Financing Strategy
- Whether Deptula-Hicks can replicate her capital-raising success at F-star for Levicept's LEVI-04 development.
- Clinical Progression
- The pace at which Levicept advances LEVI-04 through late-stage trials following positive Phase II results.
- Market Positioning
- How Levicept differentiates LEVI-04 in the competitive osteoarthritis treatment landscape.
Related topics